Hi Vin,
Many thanks. I could not agree with you more on the SIRT being ridiculously early stage and speculative. They have very limited data on very early candidates with very little mechanism -- the whole thing is a GIANT leap in the dark -- for 600 million + dollars by BP. For god's sake just drink a glass of red wine :)
In contrast, GTCB has an all but FDA approved drug, a major and significant pipeline of high probability to be approved products, a novel and potentially hugely profitable protein production platform that is a unique play on biosimilars (which will be huge and shortly so0, and reasonable probability blockbuster indications for ATIII in DIC/ CVA with good proposed mechanism . . .
SIRT was a lucky guess -- that I think unlikely to end up being a money maker for BP.
GTCB (despite their immediate lack of funds) has so many potential ways to profit, it still boggles the mind. $600 + million spent by BP here is MUCH more likely to ultimately pay off IMHO -- and yet we bumble along waiting.
A couple of years from now, we'll look back and still be shaking our head that we got in for 60cents/share . . .
Best,
MTB
Market Data 
Markets 
AI
